Aerska
Aerska has developed an antibody-oligonucleotide conjugate (AOC) platform that uses “brain shuttles” to help deliver RNAi directly to the brain, allowing for better uptake by neurons and lasting gene knockdown.
Dublin, Irelandwww.aerska.com ↗
Total raised
€51M
€50,642,458
Funding rounds
2
Investors
12
distinct backers
Active since
2025-10
latest 2026-02
Funding by year
EUR raised per year · 2026 YTDSignals
High confidenceRaise-next likelihood32
base rate 44% for Series A
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood11
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▼ Young (<3y)
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-02-09 | Series A | €33M | Age1,EQT Dementia Fund,Existing investors,Iaso Ventures | View deal → |
| 2025-10-01 | Seed | €18M | Ada Ventures,Age1,Backed VC,BlueYard,Kerna,Lingotto+3 more | View deal → |
Investors
12Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Wayflyer€2.1BIreland · E-commerce
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Oura Health€779MFinland · Healthtech